Loading clinical trials...
Loading clinical trials...
An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Dapagliflozin in Respiratory Failure in Patients With COVID-19
Conditions
Interventions
Dapagliflozin 10 milligram (mg)
Placebo
Locations
95
United States
Heart Group of the Eastern Shore
Fairhope, Alabama, United States
Baptist Hospital of Miami
Miami, Florida, United States
NorthShore University HealthSystem
Evanston, Illinois, United States
Loyola University
Maywood, Illinois, United States
Ascension - St. Vincent
Indianapolis, Indiana, United States
Lahey Health
Burlington, Massachusetts, United States
Start Date
April 22, 2020
Primary Completion Date
March 31, 2021
Completion Date
June 11, 2021
Last Updated
June 10, 2022
NCT06631287
NCT05101213
NCT04565665
NCT06871293
NCT04978571
NCT07221162
Lead Sponsor
Saint Luke's Health System
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions